

Dr. Neil Desai
Radiation Oncologist
1 Podcast on BackTable
Dr. Neil Desai is a radiation oncologist with UT Southwestern in Dallas, Texas.
Learn from the experiences and expertise of Dr. Neil Desai and other leading voices in your specialty on the BackTable app.

Episode # 41 • 01 Jun 2022
Radiotherapy for Unfavorable Intermediate Prostate Cancer
Dr. Neil Desai, a radiation oncologist with UT Southwestern, shares his perspectives on radiation therapy indications, algorithms, side effects, and prognoses for unfavorable intermediate risk prostate cancer patients.
This podcast is supported by
More from Dr. Neil Desai
About
Neil Desai, M.D., M.H.S., is an Associate Professor and Director of Clinical Research in the Department of Radiation Oncology at UT Southwestern Medical Center. Dr. Desai earned his medical degree at Yale University, where he also conducted cancer biology research that led to a master’s degree. He completed residency training in radiation oncology at Memorial Sloan Kettering Cancer Center in New York.
Dr. Desai considers it a privilege to treat patients with cancer. He says he remains inspired by his physician-scientist mentors, who demonstrated not only the great potential of bringing advances to the clinic but also the humbling need to keep a patient’s goals and values in highest focus. Dr. Desai does both as a specialist in genitourinary and hematologic malignancies and as an expert who strives to match the ideal treatment to each patient’s disease.
Between his time at Dartmouth College and Yale University School of Medicine, Dr. Desai participated in research to help determine which patients would benefit from a new class of targeted cancer drugs, and he helped develop new technologies for detecting the genetic alterations that determine a tumor’s aggressiveness.
During his residency training at Memorial Sloan Kettering Cancer Center in New York, he investigated how to apply specific treatments – including radiotherapy – to patients by considering factors such as disease biology and risk. His work culminated in the nationally recognized laboratory of David Solit, M.D., under whom he examined the impact of genetic alterations in the DNA damage response on the success of bladder-preserving chemoradiation for bladder cancer.
At UT Southwestern, Dr. Desai is committed to developing and participating in clinical trials designed to improve treatments for patients with genitourinary and hematologic cancers. He has a particular interest in prostate and bladder cancers, for which he notes that the need to improve treatment selection for a patient is as important as increasing treatment efficacy.
Visit UT Southwestern to learn more about Dr. Neil Desai.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.